These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18394448)

  • 1. Exercise-induced polymorphic ventricular tachycardia in adults without structural heart disease.
    Tan JH; Scheinman MM
    Am J Cardiol; 2008 Apr; 101(8):1142-6. PubMed ID: 18394448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
    Swan H; Laitinen P; Kontula K; Toivonen L
    J Cardiovasc Electrophysiol; 2005 Feb; 16(2):162-6. PubMed ID: 15720454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
    Tonet J; Hidden F; Naditch L; Coutte R; Himbert C; Frank R
    Ann Cardiol Angeiol (Paris); 1996 Jan; 45(1):18-23. PubMed ID: 8815771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mid-term clinical condition and prognosis in adrenergic ventricular tachycardia in children with apparently normal hearts].
    Drago F; Vignati G; Agostino DA; Mauri L; Calzolari A; Figini A; Ragonese P
    G Ital Cardiol; 1997 Apr; 27(4):349-56. PubMed ID: 9244739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
    Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
    Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
    Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholaminergic polymorphic ventricular tachycardia: a current overview.
    Leite LR; Henz BD; Macedo PG; Santos SN; Barreto JR; Zanatta A; Fenelon G; Cruz Filho FE
    Future Cardiol; 2009 Mar; 5(2):191-9. PubMed ID: 19371192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
    Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Catecholinergic ventricular tachycardia in children].
    Denjoy I; Postma A; Lupoglazoff JM; Vaksman G; Kamblock J; Leenhardt A; Wilde AA; Guicheney P
    Arch Mal Coeur Vaiss; 2005 May; 98(5):506-12. PubMed ID: 15966600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Catecholaminergic polymorphic ventricular tachycardia].
    Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
    Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M; Denjoy I; Hayashi M; Extramiana F; Maltret A; Roux-Buisson N; Lupoglazoff JM; Klug D; Maury P; Messali A; Guicheney P; Leenhardt A
    Europace; 2012 Sep; 14(9):1344-51. PubMed ID: 22383456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
    Piccini JP; Hranitzky PM; Kilaru R; Rouleau JL; White HD; Aylward PE; Van de Werf F; Solomon SD; Califf RM; Velazquez EJ
    Am J Cardiol; 2008 Dec; 102(11):1427-32. PubMed ID: 19026290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy.
    Kazemian P; Gollob MH; Pantano A; Oudit GY
    Can J Cardiol; 2011; 27(6):870.e7-10. PubMed ID: 21652165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction.
    Joshi P; Saxena A; Kaul U; Mansoor AH
    Indian Heart J; 2010; 62(1):84-6. PubMed ID: 21180045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Priori SG
    Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.
    van der Werf C; Zwinderman AH; Wilde AA
    Europace; 2012 Feb; 14(2):175-83. PubMed ID: 21893508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.